| Ytd | 42.95% | |
| 1y | 168.48% |
| Open | 34.89 | Prev Close | 35.88 | Low | 33.01 | High | 35.60 | Mkt Cap | 1.68B |
| Vol | 149.34K | Avg Vol | 139.19K | EPS | -0.58 | P/E | N/A | Forward P/E | -115.33 |
| Beta | 0.57 | Short Ratio | 0.88 | Inst. Own | 11.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-29 | 50-d Avg | 39.24 | 200-d Avg | 32.88 | 1yr Est | 54.14 |
Guggenheim analyst Paul Jeng assumes Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Pri
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse e
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other